|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: SGK223 |
Gene summary for SGK223 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | SGK223 | Gene ID | 157285 |
| Gene name | PEAK1 related, kinase-activating pseudokinase 1 | |
| Gene Alias | NACK | |
| Cytomap | 8p23.1 | |
| Gene Type | protein-coding | GO ID | GO:0000902 | UniProtAcc | Q86YV5 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 157285 | SGK223 | HTA11_99999970781_79442 | Human | Colorectum | MSS | 1.92e-04 | 1.71e-01 | 0.294 |
| 157285 | SGK223 | HTA11_99999965062_69753 | Human | Colorectum | MSI-H | 1.40e-05 | 5.85e-01 | 0.3487 |
| 157285 | SGK223 | HTA11_99999971662_82457 | Human | Colorectum | MSS | 3.52e-13 | 3.23e-01 | 0.3859 |
| 157285 | SGK223 | HTA11_99999973899_84307 | Human | Colorectum | MSS | 1.02e-09 | 3.48e-01 | 0.2585 |
| 157285 | SGK223 | HTA11_99999974143_84620 | Human | Colorectum | MSS | 3.23e-39 | 7.66e-01 | 0.3005 |
| 157285 | SGK223 | P1T-E | Human | Esophagus | ESCC | 4.13e-04 | 2.25e-01 | 0.0875 |
| 157285 | SGK223 | P2T-E | Human | Esophagus | ESCC | 1.75e-07 | 1.08e-01 | 0.1177 |
| 157285 | SGK223 | P4T-E | Human | Esophagus | ESCC | 5.32e-04 | 6.98e-02 | 0.1323 |
| 157285 | SGK223 | P5T-E | Human | Esophagus | ESCC | 1.79e-05 | 1.00e-01 | 0.1327 |
| 157285 | SGK223 | P8T-E | Human | Esophagus | ESCC | 9.00e-10 | 1.90e-01 | 0.0889 |
| 157285 | SGK223 | P9T-E | Human | Esophagus | ESCC | 3.58e-05 | 1.43e-01 | 0.1131 |
| 157285 | SGK223 | P10T-E | Human | Esophagus | ESCC | 1.53e-15 | 3.02e-01 | 0.116 |
| 157285 | SGK223 | P12T-E | Human | Esophagus | ESCC | 3.56e-15 | 3.13e-01 | 0.1122 |
| 157285 | SGK223 | P15T-E | Human | Esophagus | ESCC | 3.35e-08 | 1.56e-01 | 0.1149 |
| 157285 | SGK223 | P20T-E | Human | Esophagus | ESCC | 5.31e-12 | 1.62e-01 | 0.1124 |
| 157285 | SGK223 | P21T-E | Human | Esophagus | ESCC | 8.44e-08 | 1.52e-01 | 0.1617 |
| 157285 | SGK223 | P22T-E | Human | Esophagus | ESCC | 2.50e-03 | 1.09e-01 | 0.1236 |
| 157285 | SGK223 | P23T-E | Human | Esophagus | ESCC | 4.64e-05 | 4.30e-02 | 0.108 |
| 157285 | SGK223 | P24T-E | Human | Esophagus | ESCC | 2.89e-03 | 3.96e-02 | 0.1287 |
| 157285 | SGK223 | P26T-E | Human | Esophagus | ESCC | 1.27e-05 | 1.03e-01 | 0.1276 |
| Page: 1 2 3 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| Page: 1 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |